| Tracking Treatment Pathways in Adult Patients With Hyperkalemia. (NCT05408039) | AstraZeneca | 2022-07-14 |
| The ORTIZ Study: Optimising RASi Therapy With SZC (NCT04983979) | Barts & The London NHS Trust | 2022-06-17 |
| A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia (NCT05535920) | NephroNet, Inc. | 2022-04-14 |
| A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG) (NCT05441852) | Mayo Clinic | 2022-03-31 |
| Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects (NCT05136664) | Vifor Fresenius Medical Care Renal Pharma | 2022-02-10 |
| Lokelma for RAAS Maximisation in CKD & Heart Failure. (NCT05004363) | St George's, University of London | 2022-01-19 |
| Artificial Intelligence Identified Dyskalemia Using Electrocardiogram (AIDE) (NCT05118022) | National Defense Medical Center, Taiwan | 2022-01-01 |
| Dietary Fiber and Hyperkalemia in Dialysis Patients (NCT05860491) | Qianfoshan Hospital | 2022-01-01 |
| Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels (NCT05184998) | AstraZeneca | 2021-11-30 |
| Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects. (NCT05173584) | University of Aleppo | 2021-11-04 |
| A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (NCT05056727) | AstraZeneca | 2021-09-30 |
| Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients (NCT05029310) | Oslo University Hospital | 2021-09-01 |
| OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (NCT04789239) | Michael Fu | 2021-09-01 |
| A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia (NCT04955678) | Zeria Pharmaceutical | 2021-08-03 |
| Effect of Viscous Fiber on Postprandial Kalemic Response in Hemodialysis Patients (NCT05086185) | University of Nevada, Reno | 2021-06-29 |
| Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis (NCT04799067) | AstraZeneca | 2021-05-17 |
| A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. (NCT03528681) | AstraZeneca | 2021-05-06 |
| Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) (NCT04847232) | AstraZeneca | 2021-04-30 |
| Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia (NCT04864795) | Vifor (International) Inc. | 2021-04-19 |
| Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial) (NCT04727840) | Brigham and Women's Hospital | 2021-03-15 |
| Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects (NCT04217590) | AstraZeneca | 2020-11-16 |
| Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study (NCT04207203) | Karolinska Institutet | 2020-11-03 |
| Assessment of Hyperkalemia's Illness and Treatment Burden in Chronic Kidney Disease and Heart Failure Patients: HK Registry Pilot Study (NCT04466969) | AstraZeneca | 2020-07-31 |
| Clinical Potassium Pilot Study (NCT04251468) | Medical University of Graz | 2020-04-29 |
| Rate of Termination of Premixed Parenteral Nutrition (PN) in Surgical Patients Secondary to High Serum Electrolytes (NCT04256369) | King Faisal Specialist Hospital & Research Center | 2020-02-02 |
| Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia (NCT04012138) | Nantes University Hospital | 2019-12-20 |
| Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients (NCT03781089) | Duke University | 2019-06-20 |
| Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction (NCT04141800) | Spanish Society of Cardiology | 2019-04-30 |
| Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) (NCT03888066) | Vifor Pharma, Inc. | 2019-04-24 |
| Exploratory Study of ZG-801 for the Treatment of Hyperkalemia (NCT03799926) | Zeria Pharmaceutical | 2019-02-18 |
| Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On (NCT03597035) | University Hospitals Cleveland Medical Center | 2018-07-17 |
| Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet. (NCT03183778) | NYU Langone Health | 2018-03-12 |
| A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. (NCT03303521) | AstraZeneca | 2017-12-14 |
| The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia (NCT03326583) | Dominic Raj | 2017-11-01 |
| A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS) (NCT03283267) | AstraZeneca | 2017-10-24 |
| Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia (NCT03172702) | AstraZeneca | 2017-09-04 |
| Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (NCT03087058) | Vifor Pharma, Inc. | 2017-07-07 |
| Potassium Supplementation in CKD (NCT03253172) | Erasmus Medical Center | 2017-07-01 |
| ZS Ph2/3 Dose-response Study in Japan (NCT03127644) | AstraZeneca | 2017-06-14 |
| A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia (NCT02875834) | AstraZeneca | 2017-03-03 |
| Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease (NCT03071263) | Relypsa, Inc. | 2017-01-23 |
| A Multicenter Study to Evaluate the Nutritional Suitability of Renastart (NCT02825784) | Vitaflo International, Ltd | 2017-01-06 |
| The Effect of Mannitol on the Serum Potassium During Craniotomy (NCT03161977) | The Affiliated Hospital of Xuzhou Medical University | 2017-01-01 |
| A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia (NCT03018067) | Ardelyx | 2017-01-01 |
| Measurement of Serum Potassium Rate During Accidental Hypothermia. (NCT03096561) | University Hospital, Grenoble | 2016-11-14 |
| Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy (NCT05382988) | Guangdong Provincial People's Hospital | 2016-11-01 |
| Patiromer With or Without Food for the Treatment of Hyperkalemia (NCT02694744) | Relypsa, Inc. | 2016-02-01 |
| REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study (NCT02607085) | ZS Pharma, Inc. | 2015-10-31 |
| POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study (NCT02609841) | ZS Pharma, Inc. | 2015-09-30 |
| Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair (NCT02483702) | Valley Anesthesiology Consultants | 2015-08-01 |
| Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months (NCT02163499) | ZS Pharma, Inc. | 2014-06-30 |
| Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia. (NCT02107092) | ZS Pharma, Inc. | 2014-05-31 |
| Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. (NCT02088073) | ZS Pharma, Inc. | 2014-03-31 |
| Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns (NCT01349218) | The University of Texas Health Science Center, Houston | 2014-03-01 |
| Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients (NCT02065076) | Maisonneuve-Rosemont Hospital | 2014-02-01 |
| Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions (NCT02020317) | University of Zurich | 2014-01-01 |
| Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia (NCT01866709) | ZS Pharma, Inc. | 2013-05-01 |
| Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia (NCT01737697) | ZS Pharma, Inc. | 2012-11-30 |
| Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia (NCT01493024) | ZS Pharma, Inc. | 2011-11-30 |
| Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) (NCT01371747) | Relypsa, Inc. | 2011-06-01 |
| Evaluation of Patiromer in Heart Failure Patients (NCT00868439) | Relypsa, Inc. | 2009-04-01 |
| An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis (NCT02033317) | Relypsa, Inc. | 2008-08-01 |
| Early Protein Supplementation on Prevention of Hyperkalemia (NCT00290160) | The University of Texas Health Science Center at San Antonio | 2002-12-01 |
| Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation (NCT00162487) | Hadassah Medical Organization | 2002-08-01 |